Q1 Earnings Forecast for PRAX Issued By HC Wainwright

Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Praxis Precision Medicines in a note issued to investors on Monday, July 14th. HC Wainwright analyst D. Tsao expects that the company will earn ($4.32) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $105.00 target price on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($10.22) per share. HC Wainwright also issued estimates for Praxis Precision Medicines' Q2 2026 earnings at ($5.01) EPS, Q3 2026 earnings at ($5.02) EPS and Q4 2026 earnings at ($5.03) EPS.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its earnings results on Friday, May 2nd. The company reported ($3.29) earnings per share for the quarter, missing analysts' consensus estimates of ($3.20) by ($0.09). Praxis Precision Medicines had a negative net margin of 2,137.48% and a negative return on equity of 50.42%.

PRAX has been the topic of several other research reports. Oppenheimer upped their price target on shares of Praxis Precision Medicines from $97.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, July 8th. Wedbush raised their price target on Praxis Precision Medicines from $26.00 to $28.00 and gave the company an "underperform" rating in a report on Monday, May 5th. Needham & Company LLC reiterated a "buy" rating and set a $80.00 price target on shares of Praxis Precision Medicines in a research report on Thursday, June 12th. Finally, Chardan Capital began coverage on shares of Praxis Precision Medicines in a research report on Wednesday, May 7th. They issued a "buy" rating and a $80.00 price objective on the stock. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $94.11.

Praxis Precision Medicines Stock Up 2.5%

PRAX traded up $1.33 during trading on Wednesday, reaching $54.96. 398,802 shares of the company were exchanged, compared to its average volume of 369,879. Praxis Precision Medicines has a 12-month low of $26.70 and a 12-month high of $91.83. The company's 50-day moving average is $42.73 and its two-hundred day moving average is $50.59. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -5.11 and a beta of 2.60.

Hedge Funds Weigh In On Praxis Precision Medicines

Hedge funds and other institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. purchased a new position in shares of Praxis Precision Medicines during the 4th quarter valued at about $30,000. GAMMA Investing LLC lifted its stake in shares of Praxis Precision Medicines by 6,075.4% during the 1st quarter. GAMMA Investing LLC now owns 4,014 shares of the company's stock valued at $152,000 after buying an additional 3,949 shares in the last quarter. Graham Capital Management L.P. bought a new position in Praxis Precision Medicines in the 4th quarter worth $209,000. KLP Kapitalforvaltning AS purchased a new stake in Praxis Precision Medicines in the 4th quarter worth $215,000. Finally, Envestnet Asset Management Inc. purchased a new stake in Praxis Precision Medicines in the 4th quarter worth $231,000. 67.84% of the stock is owned by institutional investors.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.